Pfizer-Sponsored Data Presentations at ASCO20 Virtual Scientific Program

The majority of abstracts accepted for the virtual meeting will be released on Wednesday, May 13 at 5:00 pm ET, unless otherwise noted below. Oral, poster discussion, and poster sessions will be available on demand starting Friday, May 29, with the exception of the Plenary Session.

Avelumab:

(Abstract LBA1) Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Powles T. Sunday, May 31, 1:00 pm ET. Session Type: Plenary Session. Data under embargo until May 28 at 5:00 pm ET.

(Abstract 5061) Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. Bilen MA. Session Type: Poster (Poster #130). Session Title: Genitourinary Cancer – Kidney and Bladder.


Axitinib:


Bosutinib:

(Abstract 7549) Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase II/II study. Brummendorf TH. Session Type: Poster (Poster #322). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

(Abstract 7551) Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study. Sauselle S. Session Type: Poster (Poster #: 324). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

Early Oncology Development:

Biomarker analysis from a Phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). Wesolowski R. Session Type: Poster (Poster #: 137). Session Title: Breast Cancer – Metastatic.

Encorafenib + Binimetinib:

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, Phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Kopetz S. Session Type: Oral Presentation. Session Title: Gastrointestinal Cancer – Colorectal and Anal.

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Quality of life results from a randomized, three-arm, phase III study vs. the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Kopetz S. Session Type: Poster (Poster #: 31). Session Title: Gastrointestinal Cancer – Colorectal and Skin Cancer.

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. Gogas H. Session Type: Poster Discussion (Poster #: 361). Session Title: Melanoma/Skin Cancers.

A Phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). Dummer R. Type: Poster Discussion (Poster #: 371). Session Title: Melanoma/Skin Cancers.

Enzalutamide:

Final overall survival (OS) from PROSPER: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) Sternberg C. Session Type: Poster Discussion (Poster #: 96). Session Title: Genitourinary Cancer – Prostate, Testicular and Penile.

Glasdegib:

A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukaemia choose different treatment pathways. LeBlanc T. Session Type: Poster Discussion (Poster #: 293). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year survival follow-up. Heuser M. Session Type: Poster Discussion (Poster #: 282). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

Effect of early blood count recovery on response and overall survival (OS) with glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis. Wang E. Session Type: Poster (Poster #: 298). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.
(Abstract 7526) Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. Zeidan A. Session Type: Poster (Poster #: 299). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

(Abstract 7527) Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA). Wang E. Session Type: Poster (Poster #: 300). Session Title: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant.

(Abstract E19512) The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Van Beekhuizen S. Publication Only.

Palbociclib:

(Abstract 535) Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer. Calip GS. Session Type: Poster (Poster #: 27). Session Title: Breast Cancer – Local/Regional/Adjuvant.


Pan-Asset:


Rituximab:

(Abstract E20049) Factors influencing infusion-related reactions following dosing of reference rituximab (RTX) and PF-05280586, a RTX biosimilar. Courville J. Publication Only.

Talazoparib:

(Abstract 1018) Exploring impact of mutations in non-BRCA DNA Damage Response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2−) advanced breast cancer (ABC). Litton J. Session Type: Poster Discussion (Poster #: 103). Session Title: Breast Cancer – Metastatic.
(Abstract 5566) TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA). De Bono JS. Session Type: Poster (Poster #: 147). Session Title: Genitourinary Cancer – Prostate, Testicular, and Penile.


(Abstract E13076) Treatment patterns and clinical outcomes among patients (pts) with HER2+ advanced breast cancer (ABC) and germline \textit{BRCA1/2} mutation(s) (\textit{gBRCA1/2mut}): Results from a US real-world study. Obeid E. Publication Only.